Pesquisa
Educação
Soluções
Entrar
PT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Cancer Science Institute of Singapore,
Department of Biochemistry,
Yong Loo Lin School of Medicine,
Department of Biochemistry, Yong Loo Lin School of Medicine
Sudhakar Jha has not added Biography.
If you are Sudhakar Jha and would like to personalize this page please email our Author Liaison for assistance.
TIP60-miR-22 axis as a prognostic marker of breast cancer progression.
Oncotarget Dec, 2015 | Pubmed ID: 26512777
TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.
Journal of molecular cell biology Sep, 2016 | Pubmed ID: 27651430
Hypoxia is a Key Driver of Alternative Splicing in Human Breast Cancer Cells.
Scientific reports Jun, 2017 | Pubmed ID: 28642487
Stressing the (Epi)Genome: Dealing with Reactive Oxygen Species in Cancer.
Antioxidants & redox signaling Sep, 2017 | Pubmed ID: 28816066
TIP60 represses telomerase expression by inhibiting Sp1 binding to the TERT promoter.
PLoS pathogens Oct, 2017 | Pubmed ID: 29045464
Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.
Oncotarget Sep, 2017 | Pubmed ID: 29100386
Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.
PloS one , 2017 | Pubmed ID: 29145444
National University of Singapore
Yanzhou Zhang1,
Grace SuShin Chia1,
Cheng Yong Tham1,
Sudhakar Jha1,2
1Cancer Science Institute of Singapore, National University of Singapore,
2Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore
Privacidade
Termos de uso
Políticas
Entre em contato
recomende à biblioteca
Newsletter
JoVE Journal
Coleções de métodos
JoVE Encyclopedia of Experiments
Arquivo
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centro de Recursos para Docentes
Autores
Bibliotecários
Acesso
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados